Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-3,013
Closed -$387K 576
2023
Q2
$387K Buy
3,013
+88
+3% +$10.6K 0.02% 378
2023
Q1
$340K Buy
2,925
+251
+9% +$28.1K 0.02% 400
2022
Q4
$303K Buy
2,674
+95
+4% +$10.4K 0.02% 406
2022
Q3
$208K Buy
+2,579
New +$218K 0.01% 452
2022
Q2
Sell
-2,304
Closed -$295K 493
2022
Q1
$295K Buy
2,304
+476
+26% +$52.1K 0.01% 415
2021
Q4
$246K Sell
1,828
-104
-5% -$14.9K 0.01% 490
2021
Q3
$264K Sell
1,932
-44
-2% -$5.55K 0.01% 451
2021
Q2
$211K Buy
+1,976
New +$190K 0.01% 485
2016
Q1
Sell
-13,052
Closed -$267K 384
2015
Q4
$267K Sell
13,052
-320
-2% -$6.66K 0.03% 308
2015
Q3
$287K Sell
13,372
-1,012
-7% -$22.6K 0.03% 284
2015
Q2
$288K Sell
14,384
-968
-6% -$17K 0.03% 295
2015
Q1
$240K Buy
15,352
+556
+4% +$8.4K 0.03% 341
2014
Q4
$203K Buy
+14,796
New +$181K 0.02% 361

Other funds holding DXCM

Fulton Bank's DXCM Position: Q3 2023 in Review

Fulton Bank sold out of DexCom (DXCM) in Q3 2023, closing a stake of 3,013 shares — an estimated $387K sold.

Fulton Bank first reported a position in DXCM in Q4 2014 and held it in 13 quarters. The position peaked at $387K in Q2 2023. 902 funds tracked by Wall St. Rank hold DXCM as of Q3 2023.

  • Fulton Bank reported no remaining DexCom position as of Q3 2023 after selling out during the quarter.
  • Fulton Bank sold 3,013 DexCom shares in Q3 2023, an estimated $387K.
  • Fulton Bank first reported a position in DexCom in Q4 2014 and held it in 13 quarters.
  • Fulton Bank's DexCom position peaked at $387K in Q2 2023.
  • 902 funds tracked by Wall St. Rank held DexCom as of Q3 2023.

Based on Fulton Bank's 13F filing for Q3 2023, filed 4 Oct 2023.